Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
Jonathan Lim, Erasca’s chairman and chief executive officer, said the company is operating in “a really exciting point in history in targeted therapy,” as drug developers move from KRAS G12C-specific approaches toward broader pan-RAS and pan-KRAS strategies.
